Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With
September 17, 2020 17:06 ET
|
Agenus Inc.
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline
September 17, 2020 13:38 ET
|
Agenus Inc.
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
December 18, 2014 07:00 ET
|
Agenus Inc.
GSK's ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older
Agenus is entitled to receive royalties on potential commercial sales of...
Agenus Reports Second Quarter 2013 Financial Results
July 25, 2013 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today...
Agenus to Report Second Quarter 2013 Financial Results on July 25, 2013; Conference Call to Follow
July 18, 2013 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013.
Agenus executives will...
Agenus to Present at the JMP Securities Annual Healthcare Conference
July 02, 2013 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., July 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be...
Agenus to Webcast Annual Shareholders' Meeting
June 10, 2013 10:40 ET
|
Agenus Inc.
LEXINGTON, Mass., June 10, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) invites investors and the general public to its Annual Shareholders' Meeting at 5:00 p.m. ET on Wednesday, June 12, 2013....
Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors
May 22, 2013 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide...
Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting
May 01, 2013 11:20 ET
|
Agenus Inc.
LEXINGTON, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that preliminary data from a Phase 2 clinical trial showed that newly diagnosed glioblastoma multiforme...
Agenus Reports First Quarter 2013 Financial Results
April 24, 2013 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today...